Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions

Hoffmann-La Roche · NCT07741604

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
60
US sites recruiting
3
Study start
September 9, 2026
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) and safety of RO7795081, following a single oral dose in participants with renal impairment compared with participants with normal renal function.

In Part 1, participants with normal renal function and participants with severe renal impairment or kidney failure not receiving dialysis will receive RO7795081. Part 2 is optional and will be conducted based on the results of Part 1. If Part 2 is implemented, additional participants with normal renal function and participants with mild or moderate renal impairment may be enrolled to receive RO7795081.

Being studied: RO7795081

Conditions: Renal Impairment

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Ability and willingness to comply with all aspects of the protocol including completion of assessments for the duration of the study
  • Estimated Glomerular Filtration Rate (eGFR) calculated using the Body Surface Area (BSA)-adjusted Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • Participants with mild, moderate, or severe renal impairment/kidney failure and stable renal function
  • Participants with normal renal function matched to participants with renal impairment

Exclusion Criteria

  • Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
  • History or evidence of any medical condition other than renal impairment capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Surgical history of the gastrointestinal (GI) tract affecting gastric motility or altering the GI tract (with the exception of uncomplicated appendectomy and cholecystectomy)
  • History of malignancy in the past 5 years, except for fully treated local basal carcinoma, or fully treated carcinoma in situ of cervix
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • History of cardiovascular, neurologic, psychiatric, or infectious disease
  • History of hypersensitivity to any of the excipients in Glucagon-like Peptide-1 (GLP-1) agonists
  • Bipolar disorder, schizophrenia, or any other serious psychiatric condition
  • Type 1 diabetes or poorly controlled Type 2 diabetes
  • Current or recent participation in another clinical study
  • Pregnancy or breastfeeding
  • Positive Human Immunodeficiency Virus (HIV), hepatitis B, hepatitis C, or tuberculosis test
  • History of alcohol or substance abuse

Recruiting US locations

Study contacts (from the official record)

  • Reference Study ID Number: BP46039 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
All healthy volunteers studies in Florida →
A Study Investigating the Safety of RO7795081 and How the Body… (NCT07741604) | Bored Studies